BeOne Medicines (ONC) Accumulated Depreciation & Amortization (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Accumulated Depreciation & Amortization data on file, last reported at $41.1 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization rose 25.42% year-over-year to $41.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.1 million (up 25.42% YoY) and the FY2025 annual result came in at $141.7 million, down 17.51% from the prior year.
• Accumulated Depreciation & Amortization retreated to $41.1 million in Q1 2026 per ONC's latest filing, from $141.7 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $171.8 million in Q4 2024 and bottomed at $16.6 million in Q1 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $50.2 million (2024), against an average of $66.8 million.
• The widest annual swing landed in 2024, when Accumulated Depreciation & Amortization jumped 95.91%; it then declined 17.51% in 2025.
• Tracing ONC's Accumulated Depreciation & Amortization over 5 years: stood at $66.3 million in 2022, then soared by 32.28% to $87.7 million in 2023, then jumped by 95.91% to $171.8 million in 2024, then decreased by 17.51% to $141.7 million in 2025, then sank by 70.96% to $41.1 million in 2026.
• Per Business Quant, the three latest ONC Accumulated Depreciation & Amortization figures stand at $41.1 million (Q1 2026), $141.7 million (Q4 2025), and $105.7 million (Q3 2025).

Peer Comparison